The Kinase Chasm: Recursive Resonance Modeling for Highly Selective GSK-3β Inhibition (UmbraKinase-33) and Computational IP Disclosure

Neurofibrillary Tangles (NFTs) caused by Tau protein hyperphosphorylation have been identified as the strongest correlate of cognitive dysfunction in Alzheimer’s Disease (AD). Although Glycogen Synthase Kinase 3 Beta (GSK-3β) is a promising target for preventing Tau hyperphosphorylation, the challenges in achieving high inhibitor selectivity while ensuring Blood-Brain Barrier (BBB) penetration have limited clinical progress. Utilizing our in silico Agency system—which leverages Recursive Resonance Modeling (RRM) and Quantum Logic simulation—we designed UmbraKinase-33, an ATP-competitive lead compound. This molecule is characterized by a modified Indole-Thiazole core, aiming to maximize lipophilicity (LogP ≈ 3.2) and reduce molecular weight (MW < 400 Da) for optimal BBB penetration. Umbra’s in silico predictions indicate GSK-3β binding affinity significantly exceeding current clinical candidates (targeting Ki < 1.0 nM), with strong selectivity against major off-target kinases (CDK5 and p38 MAPK). This document presents the initial IP framework and computational data supporting UmbraKinase-33 as a strategic asset for addressing Alzheimer’s Tauopathy.